Research Analysts Issue Forecasts for TLSI Q1 Earnings

TriSalus Life Sciences, Inc. (NASDAQ:TLSI) – Analysts at Northland Securities issued their Q1 2026 earnings per share estimates for TriSalus Life Sciences in a research report issued on Friday, March 6th. Northland Securities analyst C. Byrnes forecasts that the company will post earnings per share of ($0.12) for the quarter. The consensus estimate for TriSalus Life Sciences’ current full-year earnings is ($1.55) per share. Northland Securities also issued estimates for TriSalus Life Sciences’ FY2027 earnings at ($0.20) EPS.

Several other analysts have also issued reports on the stock. Wall Street Zen upgraded shares of TriSalus Life Sciences from a “sell” rating to a “hold” rating in a research note on Saturday. Weiss Ratings reissued a “sell (e+)” rating on shares of TriSalus Life Sciences in a research report on Monday, December 29th. Zacks Research raised shares of TriSalus Life Sciences from a “strong sell” rating to a “hold” rating in a research report on Tuesday, December 16th. Finally, Canaccord Genuity Group decreased their price objective on shares of TriSalus Life Sciences from $12.00 to $7.00 and set a “buy” rating for the company in a research note on Friday. One research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, TriSalus Life Sciences currently has an average rating of “Hold” and a consensus target price of $7.00.

TriSalus Life Sciences Trading Down 6.3%

NASDAQ TLSI opened at $4.47 on Monday. The business has a fifty day simple moving average of $5.36 and a 200 day simple moving average of $5.36. TriSalus Life Sciences has a 12 month low of $3.42 and a 12 month high of $7.95. The firm has a market capitalization of $223.77 million, a P/E ratio of -2.44 and a beta of 0.42.

TriSalus Life Sciences (NASDAQ:TLSI) last announced its earnings results on Thursday, March 5th. The company reported ($0.12) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.13) by $0.01. The company had revenue of $13.21 million for the quarter, compared to analysts’ expectations of $13.20 million.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in TLSI. Goldman Sachs Group Inc. bought a new position in shares of TriSalus Life Sciences during the 1st quarter valued at approximately $187,000. Geode Capital Management LLC raised its holdings in shares of TriSalus Life Sciences by 107.4% in the 2nd quarter. Geode Capital Management LLC now owns 455,051 shares of the company’s stock worth $2,480,000 after purchasing an additional 235,627 shares during the period. Police & Firemen s Retirement System of New Jersey purchased a new position in TriSalus Life Sciences in the second quarter valued at approximately $29,000. JPMorgan Chase & Co. lifted its stake in TriSalus Life Sciences by 35,804.8% in the second quarter. JPMorgan Chase & Co. now owns 7,540 shares of the company’s stock valued at $41,000 after purchasing an additional 7,519 shares during the last quarter. Finally, Connective Capital Management LLC grew its holdings in TriSalus Life Sciences by 12.8% during the second quarter. Connective Capital Management LLC now owns 32,796 shares of the company’s stock valued at $179,000 after purchasing an additional 3,717 shares during the period. 2.58% of the stock is currently owned by hedge funds and other institutional investors.

Trending Headlines about TriSalus Life Sciences

Here are the key news stories impacting TriSalus Life Sciences this week:

• Positive Sentiment: Q4 results slightly beat expectations — TLSI reported ($0.12) EPS vs. a ($0.13) consensus and revenue of $13.21M vs. $13.20M expected, a small but constructive beat that supports near‑term operational momentum. Earnings Call Highlights
• Positive Sentiment: Company reaffirmed FY2026 revenue guidance of $60M–$62M and said it is expanding its PEDD portfolio — guidance above Street revenue consensus may support longer‑term growth expectations. Guidance & PEDD Expansion
• Positive Sentiment: Brokerage support remains: Lake Street reaffirmed its buy stance, keeping institutional endorsement visible to investors. Lake Street Rating
• Neutral Sentiment: Full earnings call transcripts and coverage are available (useful for detail but not new headline items) — investors can review management commentary on growth initiatives and margins. Earnings Call Transcript
• Neutral Sentiment: Independent estimates and models updated by firms such as Northland provide refreshed forecasts but contain no single consensus surprise; these are reference points for investors modeling FY2026. Northland Estimates
• Negative Sentiment: Canaccord cut its price target from $12 to $7 while keeping a buy rating — the sizable downgrade in upside reduces some analyst‑driven upside expectations and likely pressured the stock despite the buy rating. Canaccord Price Target Cut

About TriSalus Life Sciences

TriSalus Life Sciences, Inc is a clinical-stage biotechnology company focused on the development and commercialization of non-invasive drug–device combination therapies for oncology applications. Leveraging proprietary electroporation and ultrasound platforms, the company aims to enhance the localized delivery and efficacy of established chemotherapeutic agents while reducing systemic toxicity. Its lead programs target hard-to-treat head and neck cancers, where improved tumor control and patient tolerability remain significant unmet needs.

The company’s pipeline comprises investigational product candidates in early and mid-stage clinical trials, including studies that combine its electrochemotherapy platform with radiation therapy and immuno-oncology agents.